Tnfsf13-flox Mouse
一般名
Tnfsf13-flox
製品ID
S-CKO-14578
背景情報
C57BL/6JCya
系統ID
CKOCMP-69583-Tnfsf13-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Tnfsf13-flox Mouse(カタログ番号S-CKO-14578)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Tnfsf13-flox
系統ID
CKOCMP-69583-Tnfsf13-B6J-VA
遺伝子名
製品ID
S-CKO-14578
遺伝子別名
April, Tall2, Trdl1, Tnlg7b, 2310026N09Rik
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conditional knockout
染色体
Chr 11
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000018896
NCBIトランスクリプトID
NM_001159505
ターゲット領域
Exon 1~5
有効領域の大きさ
~2.3 kb
遺伝子研究の概要
Tnfsf13, also known as A proliferation-inducing ligand (APRIL), is a cytokine of the tumor necrosis factor (TNF) superfamily. It plays a crucial role in B-cell maturation, survival, proliferation, and Ig class switching [2,5,6]. It is involved in multiple signaling pathways, and its dysregulation is associated with various diseases, highlighting its biological importance. Genetic models can be used to study its function in vivo.
In human colonic epithelial cells, TNFSF13 insufficiency disrupts B-cell differentiation. TNFSF13 variant colonoids showed reduced secreted TNFSF13, increased epithelial proliferation, and reduced apoptosis. This was also confirmed in iPSC-derived colon organoids. The study identified FAS as the predominant colonic epithelial receptor for TNFSF13, and found an increase in epithelial-associated B cells in TNFSF13 variant colon tissue. Co-culture of TNFSF13 variant colonoids with memory B cells led to a reduction in IgA+ plasma cell production [1].
In hypertrophic scar, TNFSF13 was up-regulated in HS skin tissues and HSF. Recombinant TNFSF13 protein increased HSF viability, proliferation, migration, fibrosis, and inflammation by activating the NF-κB signaling pathway through interaction with HSPG2. MSC-exo alleviated HS by inhibiting the fibroblasts via the TNFSF-13/HSPG2 signaling pathway [3].
In triple-negative breast cancer, TNFSF13 upregulation correlated with a poor response to chemotherapy as it promoted autophagy initiation in chemotherapeutic-resistant TNBCs. Targeting autophagy initiation could overcome TNFSF13-related chemoresistance, suggesting TNFSF13 could be a predictive biomarker for TNBC patients receiving chemotherapy [4].
In conclusion, Tnfsf13 is essential for B-cell-related functions and is involved in multiple disease processes. Studies using gene-related models, such as the TNFSF13-variant colonoids and in vitro cell models, have revealed its role in colonic epithelial-B-cell crosstalk, hypertrophic scar formation, and chemoresistance in triple-negative breast cancer. These findings contribute to understanding the biological functions of Tnfsf13 and its implications in related diseases.
References:
1. Ma, Xianghui, Dawany, Noor, Kondo, Ayano, Kelsen, Judith R, Hamilton, Kathryn E. 2024. TNFSF13 insufficiency disrupts human colonic epithelial cell-mediated B cell differentiation. In bioRxiv : the preprint server for biology, , . doi:10.1101/2024.09.23.614260. https://pubmed.ncbi.nlm.nih.gov/39386555/
2. Dhillon, Sohita. . Telitacicept: First Approval. In Drugs, 81, 1671-1675. doi:10.1007/s40265-021-01591-1. https://pubmed.ncbi.nlm.nih.gov/34463932/
3. Zhang, Huimin, Zang, Chengyu, Zhao, Wen, Wu, Jie, Cui, Rongtao. 2023. Exosome Derived from Mesenchymal Stem Cells Alleviates Hypertrophic Scar by Inhibiting the Fibroblasts via TNFSF-13/HSPG2 Signaling Pathway. In International journal of nanomedicine, 18, 7047-7063. doi:10.2147/IJN.S433510. https://pubmed.ncbi.nlm.nih.gov/38046235/
4. Lin, Hui-Yu, Kuei, Chia-Hao, Lee, Hsun-Hua, Chen, Chi-Long, Lin, Yuan-Feng. 2020. TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer. In Journal of molecular medicine (Berlin, Germany), 98, 1255-1267. doi:10.1007/s00109-020-01952-5. https://pubmed.ncbi.nlm.nih.gov/32671412/
5. Mackay, Fabienne, Schneider, Pascal, Rennert, Paul, Browning, Jeffrey. 2001. BAFF AND APRIL: a tutorial on B cell survival. In Annual review of immunology, 21, 231-64. doi:. https://pubmed.ncbi.nlm.nih.gov/12427767/
6. Cheung, Chee Kay, Barratt, Jonathan, Lafayette, Richard, Zhang, Hong, Rizk, Dana V. 2024. Targeting APRIL in the treatment of glomerular diseases. In Kidney international, 106, 806-818. doi:10.1016/j.kint.2024.08.012. https://pubmed.ncbi.nlm.nih.gov/39182759/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
